HERON THERAPEUTICS, INC. /DE/

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

HRTX$0.37+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income

(In thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Net product sales	$37,666	$37,200	$72,377	$76,103
Cost of product sales	11,572	9,857	22,210	18,314
Gross profit	26,094	27,343	50,167	57,789
Operating expenses:
Research and development	2,702	2,934	5,087	5,213
General and administrative	11,276	14,471	23,421	27,173
Sales and marketing	14,160	11,575	28,468	23,886
Total operating expenses	28,138	28,980	56,976	56,272
(Loss) income from operations	(2,044)	(1,637)	(6,809)	1,517
Other expense, net	(3,445)	(744)	(6,791)	(1,263)
Net (loss) income	(5,489)	(2,381)	(13,600)	254
Other comprehensive (loss) income:
Unrealized loss on short-term investments	-	(2)	(10)	(14)
Comprehensive (loss) income	$(5,489)	$(2,383)	$(13,610)	$240
Basic net (loss) income per share	$(0.03)	$(0.02)	$(0.07)	$0.00
Diluted net (loss) income per share	$(0.03)	$(0.02)	$(0.07)	$0.00
Weighted average common shares outstanding, basic	190,335	154,020	189,993	153,804
Weighted average common shares outstanding, diluted	190,335	154,020	189,993	197,751

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.